Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome

Pediatric Pulmonology

Volumn 39, Issue 1, 2005, Pages 64-69

  Lam, Barbara C C ^a,b   Yiu, Ki Ng ^a   Kar, Yin Wong ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Prematurity; Respiratory distress syndrome; Surfactant

Indexed keywords

BERACTANT; BLES; DIPALMITOYLPHOSPHATIDYLCHOLINE; LIPID; SURFACTANT; UNCLASSIFIED DRUG;

ARTICLE; ARTIFICIAL VENTILATION; BIRTH WEIGHT; CHRONIC LUNG DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; HUMAN; MORTALITY; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN INTENSIVE CARE; OXYGEN CONSUMPTION; OXYGENATION; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBSTITUTION THERAPY; TREATMENT OUTCOME;

BIOLOGICAL PRODUCTS; FEMALE; HOSPITALS, TEACHING; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; INFANT, PREMATURE; LUNG DISEASES; MALE; OXYGEN; PULMONARY SURFACTANTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN; TREATMENT OUTCOME;

EID: 10344259084     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20125     Document Type: Article

References (24)

1. Schwartz RM, Luby AM, Scanlon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality, and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 1994;330:1476-1480.
2. Ross Products Division, Abott Laboratories. Survanta (beractant) intratracheal suspension package insert Columbus. OH: Ross Products Division, Abott Laboratories; 1999.
3. Burroughs Wellcome. Exosurf neonatal (colfosceril palmitate, cetyl, alcohol, tyloxapol) for intratracheal suspension. Package insert. Research Triangle Park, NC: Burroughs Wellcome; 1990.
4. Horbar JD, et al. A multicenter randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. J Pediatr 1993;123:757-766.
5. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of Infrasurf (calf lung surfacant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 1997;100:31-38.
6. Amirkhanian JD, Kheiter A, Merritt TA. Comparative evaluation of reduction in surface-tension lowering ability of Survanta and KL4 surfactant by some serum components. Pediatr Res 1994;1929:324A.
7. Mizuno K, Ekegami M, Chan CM, et al. In vivo function of the modified natural surfactant. Pediatr Res 1994;2055:A345.
8. Hall SB, Venkitaraman AR, Whitsett JA, et al. Importance of hydrophobic apoproteins as constituents of clinical exogenous surfactants. Am Rev Respir Dis 1992;145:24.
9. Seeger W, Grube C, Günther A, Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur Respir J 1993;6:971-977.
10. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995;95:32-36.
11. Pandit PB, Dunn MS, Kelly EN, Perlman M. Surfactant replacement in neonates with early chronic lung disease. Pediatrics 1995;95:851-854.
12. Ikegami M, Adams FH, Towers B, Osher AB. The quantity of natural surfactant necessary to prevent the respiratory distress syndrome in premature lambs. Pediatr Res 1980;14:1082-1085.
13. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1993;69:276-280.
14. Valls-i-Soler A, Lopez-Heredia J, Fernandez-Ruanova MB, Gastiasoro E. A simplified surfactant dosing procedure in respiratory distress syndrome: the "side-hole" randomized study. Spanish Surfactant Collaborative Group. Acta Paediatr 1997;86: 747-751.
15. Zola EM, Gunkel JH, Chan RK, Lim MO, Knox I, Feldman BH, et al. Comparison of three dosing procedures for administration of bovine surfactant to neonates with respiratory distress syndrome. J Pediatr 1993;122:453-459.
16. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Ega EA, Trout JR, et al. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome. Pediatircs 1997;100:31-38.
17. Speer CP, Gefeller O, Groneck P, Laufkotter E, Roll C, Hanssler L, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1995;72:8-13.
18. Otsubo E, Takei T. Effects of the human pulmonary surfactant protein C (SP-C), SP-CL1(6-28) on surface activities of surfactants with various phospholipids. Biol Pharm Bull 2002;25:1303-1306.
19. Walther FJ, Hernandez-Juviel J, Mercado PE, Gordon LM, Waring AJ. Surfactant with SP-B and SP-C analogues improves lung function in surfactant-deficient rats. Biol Neonate 2002;82:181-187.
20. Walther FJ, Hernandez-Juviel J, Bruni R, Waring AJ. Spiking Survanta with synthetic surfactant peptides improves oxygenation in surfactant-deficient rats. Ame J Respir Crit Care Med 1997;156:855-861.
21. Walther FJ, Hernandez-Juviel J, Bruni R, Waring AJ. Protein composition of synthetic surfactant affects gas exchange in surfactant-deficient rats. Pediatr Res 1998;43:666-673.
22. Häfner D, Germann P, Hauschke D. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am J Respir Crit Care Med 1998;158:270-278.
23. Cole FS, Hamvas A, Nogee LM. Genetic disorders of neonatal respiratory function. Pediatr Res 2001;50:157-162.
24. El-Amin EO, Sharma PP. Surfactant therapy in the absence of respiratory support facilities. J Trop Pediatr 2003;49:61-63.